// App-Quantinova.ai

162 : Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study.

Researchers

Presenter

  • Scott Kopetz

Principal Investigators

  • Danielle A. Murphy

  • Jie Pu

  • Rona Yaeger

  • Fortunato Ciardiello

  • Jayesh Desai

  • Eric Van Cutsem

  • Harpreet Singh Wasan

  • Takayuki Yoshino

  • Elena Elez

  • Adele Golden

  • Zhou Zhu

  • Xiaosong Zhang

  • Josep Tabernero

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Pfizer Oncology, La Jolla, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Universita Della Campania "Luigi Vanvitelli", Napoli, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • National Cancer Center, EPOC, Chiba, Japan

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Pfizer Inc., Cambridge, MA

Locations

  • United States

  • Italy

  • Australia

  • Belgium

  • United Kingdom

  • Japan

  • Spain

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Circulating DNA

Drug/Treatment

  • Binimetinib

  • Encorafenib

  • Erbitux

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT04607421

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved